Search research articles
Contact Us
Filters
Showing results (51-60 of 59) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 59 results.
The Journal of Biological Chemistry
|
May 31, 2013
Anthrax SET protein: a potential virulence determinant that epigenetically represses NF-κB activation in infected macrophages
Shiraz Mujtaba, Benjamin Y Winer, Anbalagan Jaganathan, et al.
The Journal of Infectious Diseases
|
February 17, 2024
The Engineered Lysin CF-370 Is Active Against Antibiotic-Resistant Gram-Negative Pathogens In Vitro and Synergizes With Meropenem in Experimental Pseudomonas aeruginosa Pneumonia
Karen Sauve, Aubrey Watson, Jun T Oh, et al.
Journal of Molecular Biology
|
December 22, 2006
The 1.6 A crystal structure of the catalytic domain of PlyB, a bacteriophage lysin active against Bacillus anthracis
Corrine J Porter, Raymond Schuch, Adam J Pelzek, et al.
The Journal of Infectious Diseases
|
November 30, 2013
Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia
Raymond Schuch, Han M Lee, Brent C Schneider, et al.
The Journal of Clinical Investigation
|
April 10, 2020
Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis
Vance G Fowler, Anita F Das, Joy Lipka-Diamond, et al.
Plos One
|
April 18, 2013
Use of a bacteriophage lysin to identify a novel target for antimicrobial development
Raymond Schuch, Adam J Pelzek, Assaf Raz, et al.
The Journal of Antimicrobial Chemotherapy
|
December 4, 2025
In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis
María-Alexandra Cañas, Guillermo Cuervo, Javier García-González, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 1, 2024
Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT)
Vance G Fowler, Anita F Das, Joy Lipka-Diamond, et al.
ACS Medicinal Chemistry Letters
|
January 21, 2014
Discovery of Novel Putative Inhibitors of UDP-GlcNAc 2-Epimerase as Potent Antibacterial Agents
Yong Xu, Benjamin Brenning, Adrianne Clifford, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 59) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 59 results.
The Journal of Biological Chemistry
|
May 31, 2013
Anthrax SET protein: a potential virulence determinant that epigenetically represses NF-κB activation in infected macrophages
Shiraz Mujtaba, Benjamin Y Winer, Anbalagan Jaganathan, et al.
The Journal of Infectious Diseases
|
February 17, 2024
The Engineered Lysin CF-370 Is Active Against Antibiotic-Resistant Gram-Negative Pathogens In Vitro and Synergizes With Meropenem in Experimental Pseudomonas aeruginosa Pneumonia
Karen Sauve, Aubrey Watson, Jun T Oh, et al.
Journal of Molecular Biology
|
December 22, 2006
The 1.6 A crystal structure of the catalytic domain of PlyB, a bacteriophage lysin active against Bacillus anthracis
Corrine J Porter, Raymond Schuch, Adam J Pelzek, et al.
The Journal of Infectious Diseases
|
November 30, 2013
Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia
Raymond Schuch, Han M Lee, Brent C Schneider, et al.
The Journal of Clinical Investigation
|
April 10, 2020
Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis
Vance G Fowler, Anita F Das, Joy Lipka-Diamond, et al.
Plos One
|
April 18, 2013
Use of a bacteriophage lysin to identify a novel target for antimicrobial development
Raymond Schuch, Adam J Pelzek, Assaf Raz, et al.
The Journal of Antimicrobial Chemotherapy
|
December 4, 2025
In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis
María-Alexandra Cañas, Guillermo Cuervo, Javier García-González, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 1, 2024
Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT)
Vance G Fowler, Anita F Das, Joy Lipka-Diamond, et al.
ACS Medicinal Chemistry Letters
|
January 21, 2014
Discovery of Novel Putative Inhibitors of UDP-GlcNAc 2-Epimerase as Potent Antibacterial Agents
Yong Xu, Benjamin Brenning, Adrianne Clifford, et al.
Page
of 6